Literature DB >> 25251804

The effect of ivacaftor in adolescents with cystic fibrosis (G551D mutation): an exercise physiology perspective.

Zoe Louise Saynor1, Alan Robert Barker, Patrick John Oades, Craig Anthony Williams.   

Abstract

PURPOSE: The purpose of this report was to evaluate the influence of 12 weeks of ivacaftor treatment on the aerobic function of 2 teenage patients with cystic fibrosis (CF; ΔF508/G551D) using a maximal cardiopulmonary exercise test. SUMMARY OF KEY POINTS: One patient, with relatively mild disease, demonstrated no clinically meaningful changes in maximal oxygen uptake ((Equation is included in full-text article.)O2max). However, in the second case, with more established lung disease on imaging, (Equation is included in full-text article.)O2max improved by approximately 30%, an improvement out of proportion with early lung function changes. This improvement resulted from increased muscle oxygen delivery and extraction. STATEMENT OF
CONCLUSIONS: Cardiopulmonary exercise testing can monitor the extent and cause(s) of change following interventions such as ivacaftor, with the potential to identify functional changes independent from spirometry indices. RECOMMENDATIONS FOR CLINICAL PRACTICE: Cardiopulmonary exercise testing represents an important and comprehensive clinical assessment tool, and its use as an outcome measure in the functional assessment of patients with CF is encouraged.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25251804     DOI: 10.1097/PEP.0000000000000086

Source DB:  PubMed          Journal:  Pediatr Phys Ther        ISSN: 0898-5669            Impact factor:   3.049


  4 in total

1.  PharmGKB summary: very important pharmacogene information for CFTR.

Authors:  Ellen M McDonagh; John P Clancy; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-03       Impact factor: 2.089

Review 2.  Toward the Establishment of New Clinical Endpoints for Cystic Fibrosis: The Role of Lung Clearance Index and Cardiopulmonary Exercise Testing.

Authors:  Elpis Hatziagorou; Asterios Kampouras; Vasiliki Avramidou; Ilektra Toulia; Elisavet-Anna Chrysochoou; Maria Galogavrou; Fotios Kirvassilis; John Tsanakas
Journal:  Front Pediatr       Date:  2021-02-25       Impact factor: 3.418

3.  Long-term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation.

Authors:  M Marcella Burghard; G Gitte Berkers; S Sophie Ghijsen; Fm Francis Hollander-Kraaijeveld; Km Karin de Winter-de Groot; Ck Kors van der Ent; Hgm Harry Heijerman; T Tim Takken; Hj Erik Hulzebos
Journal:  Pediatr Pulmonol       Date:  2020-03-31

4.  Exercise Intolerance in Cystic Fibrosis: Importance of Skeletal Muscle.

Authors:  Paula Rodriguez-Miguelez; Nichole Seigler; Haruki Ishii; Reva Crandall; Kathleen T McKie; Caralee Forseen; Ryan A Harris
Journal:  Med Sci Sports Exerc       Date:  2021-04-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.